A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Aug 2016 Status changed from recruiting to completed.
- 13 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 13 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016.